Advertisement

Topics

Icon Bioscience Inc. Company Profile

12:42 EDT 25th March 2019 | BioPortfolio

Icon Bioscience, Inc. is a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome® drug delivery technology. The technology encompasses a broad number of related, but distinct drug delivery systems capable of incorporating an extensive range of active agents, including small molecules, proteins and monoclonal antibodies. Moreover, this drug delivery platform is a highly advanced, yet elegantly formulated system for controlling the release of medication within the eye for up to a year through the administration of a single injection. The technology’s exceptional versatility can support products individually formulated to meet the particular clinical requirements of a given active agent targeting a specific ophthalmic disease. Icon is actively developing a broad portfolio of specialty pharmaceuticals targeting several ophthalmic indications, including macular edema, glaucoma, age-related macular degeneration and cataract surgery. For additional information visit the Icon website at www.iconbioscience.com


News Articles [415 Associated News Articles listed on BioPortfolio]

ICON Acquires MolecularMD

Deal brings to ICON expanded testing platforms, including next generation sequencing, and immunohistochemistry (IHC)

ICON Acquires Precision Medicine for Oncology Company MolecularMD

ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision...

ICON buys US molecular diagnostics lab

MolecularMD, a molecular diagnostics lab based in Portland, Ore., was acquired by ICON for an undisclosed amount.  -More- 

Icon introduces new drug safety reporting solution

Iconâs new drug safety reporting platform automates complex processes to ensure compliance in the âever-changingâ regulatory environment, says VP.

R B and Pop Icon Valerie Simpson and Pulitzer Prize-Winning Composer Melinda Wagner Receive Top ...

NEW YORK, Dec. 12, 2018 /PRNewswire/ -- The ASCAP Foundation honored R&B and pop icon Valerie Simpson with its George M. Cohan Friars Foundation Award Read more...

Aytu BioScience, Inc.: Aytu BioScience Announces Pricing of $13.2 Million Underwritten Public Offering

ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant ...

Icon launches technology for adaptive clinical trial design

Icon has launched an integrated technology platform for the design, simulation, and analysis of adaptive clinical trials.

Aytu BioScience, Inc.: Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant...

Drugs and Medications [24 Associated Drugs and Medications listed on BioPortfolio]

Tetracaine hydrochloride [bausch & lomb incorporated]

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% (Sterile) Rx only

Tetracaine hydrochloride [amici pharmaceuticals llc]

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% (Sterile) Rx only

Tetracaine hydrochloride [preferred pharmaceuticals, inc.]

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% (Sterile) Rx only

Gentamicin sulfate [proficient rx lp]

Gentamicin Sulfate Ophthalmic Solution USP, 0.3% (Sterile)

Erythromycin [proficient rx lp]

Erythromycin Ophthalmic Ointment USP, 0.5% (Sterile)

Clinical Trials [19 Associated Clinical Trials listed on BioPortfolio]

The Effect of ICON Treatment on WPL With Patients After Fixed Orthodontic Appliances

The aim of this study is to determine the effect of ICON on White spot lesions compared to CPP-ACPF plus.

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept ...

Randomized Controlled Crossover Comparison of Icon Underwear to Disposable Pads

This is a randomized cross over trial to compare quality of life and product performance between Icon reusable underwear versus standard disposable pad in patients with mild to moderate ur...

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholi...

Non-invasive Monitor in Endoscopic Invasive Procedure

We include the patients who need painless invasive endoscopic precedure, we collect the dempgraphic data and apply the non-invasive device ICON on patients during the who procedure.

Companies [340 Associated Companies listed on BioPortfolio]

Icon Bioscience, Inc.

Icon Bioscience, Inc., (IBI), is a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals based on its Verisome(TM) drug...

Icon Bioscience Inc.

Icon Bioscience, Inc. is a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its pa...

ICON Clinical Research

ICON was founded in 1990 by a group of experienced professionals, who were dedicated to providing the pharmaceutical and biotechnology industries with exceptional clinical research and biometric servi...

ICON Eyecare

ICON Eyecare is a leading surgical and medical eye care provider, based out of Denver, CO. Since 1999, ICON has been building a Center of Ophthalmology Excellence empowered by an ...

ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic devel...

More Information about "Icon Bioscience Inc." on BioPortfolio

We have published hundreds of Icon Bioscience Inc. news stories on BioPortfolio along with dozens of Icon Bioscience Inc. Clinical Trials and PubMed Articles about Icon Bioscience Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Icon Bioscience Inc. Companies in our database. You can also find out about relevant Icon Bioscience Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...


Corporate Database Quicklinks



Searches Linking to this Company Record